Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling

Glycobiology

Volumn 26, Issue 2, 2015, Pages 166-180

  Binnington, Beth ^a   Nguyen, Long ^a   Kamani, Mustafa ^a,b   Hossain, Delowar ^a   Marks, David L ^c   Budani, Monique ^a,b   Lingwood, Clifford A ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

glucosylceramide; Golgi; lactotriaosylceramide; UGCG; Verotoxin cholera toxin retrograde transport

Indexed keywords

ATORVASTATIN; CHOLERA TOXIN; GERANYLGERANYL PYROPHOSPHATE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; GLYCOSYLTRANSFERASE; ISOPRENOID; MEVINOLIN; RAB PROTEIN; ROSUVASTATIN; VEROTOXIN 1; CERAMIDE; GERANYLTRANSFERASE; HYPOCHOLESTEROLEMIC AGENT;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOSOL; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GOLGI COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIPID METABOLISM; MALE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; STEADY STATE; TRANS GOLGI NETWORK; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; JURKAT CELL LINE; MCF-7 CELL LINE; METABOLISM; PROTEIN PRENYLATION; PROTEIN TRANSPORT;

ANTICHOLESTEREMIC AGENTS; CERAMIDES; GERANYLTRANSTRANSFERASE; GOLGI APPARATUS; HUMANS; JURKAT CELLS; MCF-7 CELLS; PROTEIN PRENYLATION; PROTEIN TRANSPORT; RAB GTP-BINDING PROTEINS;

EID: 84960353036     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv084     Document Type: Article

References (117)

1. Agola JO, Jim PA, Ward HH, Basuray S, Wandinger-Ness A. 2011. Rab GTPases as regulators of endocytosis, targets of disease and therapeutic opportunities. Clin Genet. 80(4):305-318.
2. Beltowski J,Wojcicka G, Jamroz-Wisniewska A. 2009. Adverse effects of statins -Mechanisms and consequences. Current Drug Safety. 4(3):209-228.
3. Bianchi P, Fermo E, Vercellati C, Boschetti C, Barcellini W, Iurlo A, Marcello AP, Righetti PG, Zanella A. 2009. Congenital dyserythropoietic anemia type II (CDAII) is caused by mutations in the SEC23B gene. Human Mutation. 30(9):1292-1298.
4. Bietrix F, Lombardo E, van Roomen CP, Ottenhoff R, Vos M, Rensen PC, Verhoeven AJ, Aerts JM, Groen AK. 2010. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE∗3 Leiden and low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol. 30(5):931-937.
5. Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. 2009. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology. 49(2):637-645.
6. Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM. 2007. Identification of the nonlysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem. 282(2):1305-1312.
7. Bouhours JF, Bouhours D, Delaunay J. 1985. Abnormal fatty acid composition of erythrocyte glycosphingolipids in congenital dyserythropoietic anemia type II. J Lipid Res. 26(4):435-441.
8. Boyd B, Richardson S, Gariepy J. 1991. Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin. Infect Immun. 59(3):750-757.
9. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. 2013. Risk of incident diabetes among patients treated with statins: Population based study. BMJ. 346:f2610.
10. Cole SL, Grudzien A, Manhart IO, Kelly BL, Oakley H, Vassar R. 2005. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretasecleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem. 280(19):18755-18770.
11. Cordle A, Koenigsknecht-Talboo J,Wilkinson B, Limpert A, Landreth G. 2005. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem. 280(40):34202-34209.
12. Correale M, Abruzzese S, Greco CA, Concilio M, Di Biase M, Brunetti ND. 2012. Statins in heart failure. Curr Vasc Pharmacol.
13. Cottam NP, Ungar D. 2012. Retrograde vesicle transport in the Golgi. Protoplasma. 249(4):943-955.
14. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ. 2005. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 37(3):349-358.
15. D'Angelo G, Polishchuk E, Di Tullio G, Santoro M, Di Campli A, Godi A, West G, Bielawski J, Chuang CC, van der Spoel AC, et al. 2007. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature. 449(7158):62-67.
16. D'Angelo G, Uemura T, Chuang CC, Polishchuk E, SantoroM, Ohvo-Rekila H, Sato T, Di Tullio G, Varriale A, D'Auria S, et al. 2013. Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. Nature. 501(7465):116-120.
17. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU. 2009. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 4(9):e6951.
18. Davis AR, Alevy YG, Chellaiah A, Quinn MT, Mohanakumar T. 1998. Characterization of HDJ-2, a human 40 kD heat shock protein. Int J Biochem Cell Biol. 30(11):1203-1221.
19. Deguchi H, Fernandez JA, Pabinger I, Heit JA, Griffin JH. 2001. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood. 97(7): 1907-1914.
20. Dekker N, Voorn-Brouwer T, Verhoek M,Wennekes T, Narayan RS, Speijer D, Hollak CE, Overkleeft HS, Boot RG, Aerts JM. 2011. The cytosolic betaglucosidase GBA3 does not influence type 1 Gaucher disease manifestation. Blood Cells Mol Dis. 46(1):19-26.
21. Di Sano F, Fazi B, Citro G, Lovat PE, Cesareni G, Piacentini M. 2003. Glucosylceramide synthase and its functional interaction with RTN-1C regulate chemotherapeutic-induced apoptosis in neuroepithelioma cells. Cancer Res. 63(14):3860-3865.
22. Dohi T, Nores G, Hakomori S. 1988. An IgG3 monoclonal antibody established after immunization with GM3 lactone: Immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res. 48(20):5680-5685.
23. Fantini J, Barrantes FJ. 2013. How cholesterol interacts with membrane proteins: An exploration of cholesterol-binding sites including CRAC, CARC, and tilted domains. Front Physiol. 4:31.
24. Fenderson BA, Hahnel AC, Eddy EM. 1983. Immunohistochemical localization of two monoclonal antibody-defined carbohydrate antigens during early murine embryogenesis. Dev Biol. 100(2):318-327.
25. Fuchs E, Haas AK, Spooner RA, Yoshimura S, Lord JM, Barr FA. 2007. Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways. J Cell Biol. 177(6):1133-1143.
26. Furukawa K, Ohkawa Y, Yamauchi Y, Hamamura K, Ohmi Y. 2012. Fine tuning of cell signals by glycosylation. J Biochem. 151(6):573-578.
27. Futerman AH, Pagano RE. 1991. Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem J. 280(Pt 2):295-302.
28. Gault CR, Obeid LM, Hannun YA. 2010. An overview of sphingolipid metabolism: From synthesis to breakdown. Adv Exp Med Biol. 688:1-23.
29. Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, Groener JE. 2008. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 389(1-2):109-113.
30. Giussani P, Colleoni T, Brioschi L, Bassi R, Hanada K, Tettamanti G, Riboni L, Viani P. 2008. Ceramide traffic in C6 glioma cells: Evidence for CERTdependent and independent transport from ER to the Golgi apparatus. Biochim Biophys Acta. 1781(1-2):40-51.
31. Glaros EN, Kim WS, Quinn CM,Wong J, Gelissen I, JessupW, Garner B. 2005. Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/ apolipoprotein A-I pathway: 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J Biol Chem. 280(26): 24515-24523.
32. Gomes AQ, Ali BR, Ramalho JS, Godfrey RF, Barral DC, Hume AN, Seabra MC. 2003. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell. 14(5):1882-1899.
33. Halter D, Neumann S, van Dijk SM, Wolthoorn J, de Maziere AM, Vieira OV, Mattjus P, Klumperman J, van Meer G, Sprong H. 2007. Pre-and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol. 179(1):101-115.
34. Henion TR, Zhou D,Wolfer DP, Jungalwala FB, Hennet T. 2001. Cloning of a mouse beta 1,3-N-acetylglucosaminyltransferase GlcNAc(beta 1,3)Gal (beta 1,4)Glc-ceramide synthase gene encoding the key regulator of lactoseries glycolipid biosynthesis. J Biol Chem. 276(32):30261-30269.
35. Holmes EH, Hakomori S, Ostrander GK. 1987. Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed beta 1-3N-acetylglucosaminyltransferase. J Biol Chem. 262(32):15649-15658.
36. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. 2006. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol. 57(2):155-164.
37. Hutagalung AH, Novick PJ. 2011. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 91(1):119-149.
38. Ichikawa S, SakiyamaH, Suzuki G,Hidari KI,Hirabayashi Y. 1996. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc Natl Acad Sci USA. 93(10):4638-4643.
39. Ishitsuka R, Hirabayashi Y, Kobayashi T. 2009. Glycosphingolipid deficiency increases the sterol regulatory element-mediated gene transcription. Biochem Biophys Res Commun. 378(2):240-243.
40. Ivessa NE, Gravotta D, De Lemos-Chiarandini C, Kreibich G. 1997. Functional protein prenylation is required for the brefeldin A-dependent retrograde transport from the Golgi apparatus to the endoplasmic reticulum. J Biol Chem. 272(33):20828-20834.
41. Jeckel D, Karrenbauer A, Burger KN, van Meer G, Wieland F. 1992. Glucosylceramide is synthesized at the cytosolic surface of various Golgi subfractions. J Cell Biol. 117(2):259-267.
42. Kamani M, Mylvaganum M, Tian R, Binnington B, Lingwood C. 2011. Adamantyl glycosphingolipids provide a new approach to the selective regulation of cellular glycosphingolipid metabolism. J Biol Chem. 286:21413-21426.
43. Karman J, Tedstone JL, Gumlaw NK, Zhu Y, Yew N, Siegel C, Guo S, Siwkowski A, Ruzek M, Jiang C, et al. 2010. Reducing glycosphingolipid biosynthesis in airway cells partially ameliorates disease manifestations in a mouse model of asthma. Int Immunol. 22(7):593-603.
44. Kawashima N, Yoon SJ, Itoh K, Nakayama K. 2009. Tyrosine kinase activity of epidermal growth factor receptor is regulated byGM3 binding through carbohydrate to carbohydrate interactions. J Biol Chem. 284(10):6147-6155.
45. Kean EL. 1966. Separation of gluco-and galactocerebrosides by means of borate thin-layer chromatography. J Lipid Res. 7(3):449-452.
46. Kinsella BT, Maltese WA. 1991. rab GTP-binding proteins implicated in vesicular transport are isoprenylated in vitro at cysteines within a novel carboxyl-terminal motif. J Biol Chem. 266(13):8540-8544.
47. Kinsella BT, Maltese WA. 1992. rab GTP-binding proteins with three different carboxyl-terminal cysteine motifs are modified in vivo by 20-carbon isoprenoids. J Biol Chem. 267(6):3940-3945.
48. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ. 2008. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J Clin Endocrinol Metab. 93(3):845-851.
49. Le Pendu J, Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Clement M. 2001. ABH and Lewis histo-blood group antigens in cancer. APMIS. 109(1):9-31.
50. Lee L, Abe A, Shayman JA. 1999. Improved inhibitors of glucosylceramide synthase. J Biol Chem. 274(21):14662-14669.
51. Lingwood D, Binnington B, Róg T, Vattulainen I, Grzybek M, Coskun U, Lingwood C, Simons K. 2011. Cholesterol modulates glycolipid conformation and receptor activity. Nat Chem Biol. 7:260-262.
52. Linstedt AD, Hauri HP. 1993. Giantin, a novel conserved Golgi membrane protein containing a cytoplasmic domain of at least 350 kDa. Mol Biol Cell. 4(7):679-693.
53. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. 2009. Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 119(1):131-138.
54. Liu S, Storrie B. 2012. Are Rab proteins the link between Golgi organization and membrane trafficking? Cell Mol Life Sci. 69(24):4093-4106.
55. Liu YY, Yu JY, Yin D, Patwardhan GA, Gupta V, Hirabayashi Y, Holleran WM, Giuliano AE, Jazwinski SM, Gouaze-Andersson V, et al. 2008. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 22(7):2541-2551.
56. Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, et al. 2001. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61(24):8758-8768.
57. Lowry RR. 1968. Ferric chloride spray detector for cholesterol and cholesteryl esters on thin-layer chromatograms. J Lipid Res. 9(3):397.
58. Mahfoud R, Manis A, Binnington B, Ackerley C, Lingwood CA. 2010. A major fraction of glycosphingolipids in model and cellular cholesterol containing membranes are undetectable by their binding proteins. J Biol Chem. 285(46):36049-36059.
59. Majoul I, Schmidt T, Pomasanova M, Boutkevich E, Kozlov Y, Soling HD. 2002. Differential expression of receptors for Shiga and Cholera toxin is regulated by the cell cycle. J Cell Sci. 115(Pt 4):817-826.
60. Marks DL, Dominguez M, Wu K, Pagano RE. 2001. Identification of active site residues in glucosylceramide synthase. A nucleotide-binding catalytic motif conserved with processive beta-glycosyltransferases. J Biol Chem. 276(28):26492-26498.
61. Marks DL, Wu K, Paul P, Kamisaka Y, Watanabe R, Pagano RE. 1999. Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. J Biol Chem. 274(1):451-456.
62. Maxzud MK, Maccioni HJ. 2000. Glucosylceramide synthesized in vitro from endogenous ceramide is uncoupled from synthesis of lactosylceramide in Golgi membranes from chicken embryo neural retina cells. Neurochem Res. 25(1):145-152.
63. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. 2011. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 146(1):37-52.
64. Merrill AH Jr. 2011. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev. 111(10):6387-6422.
65. Miller M, DiNicolantonio JJ, Can M, Grice R, Damoulakis A, Serebruany VL. 2013. The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome. Cardiology. 125(2):74-77.
66. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. 2001. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma. 40(5-6):659-662.
67. Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW. 2006. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 176(12):7657-7665.
68. Mukherjee S, Zha X, Tabas I, Maxfield FR. 1998. Cholesterol distribution in living cells: Fluorescence imaging using dehydroergosterol as a fluorescent cholesterol analog. Biophys J. 75(4):1915-1925.
69. Nakamura N. 2010. Emerging new roles of GM130, a cis-Golgi matrix protein, in higher order cell functions. J Pharmacol Sci. 112(3):255-264.
70. Nakamura N, Rabouille C,Watson R, Nilsson T, Hui N, Slusarewicz P, Kreis T, G. W. 1995. Characterization of a cis-Golgi matrix protein, GM130. J Cell Biol. 131:1715-1726.
71. Nakamura M, Tsunoda A, Sakoe K, Gu J, Nishikawa A, Taniguchi N, Saito M. 1992. Total metabolic flow of glycosphingolipid biosynthesis is regulated by UDP-GlcNAc:lactosylceramide beta 1->3N-acetylglucosaminyltransferase and CMP-NeuAc:lactosylceramide alpha 2->3 sialyltransferase in human hematopoietic cell line HL-60 during differentiation. J Biol Chem. 267(33):23507-23514.
72. Neufeld EB, Wastney M, Patel S, Suresh S, Cooney AM, Dwyer NK, Roff CF, Ohno K, Morris JA, Carstea ED, et al. 1999. The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem. 274(14):9627-9635.
73. Nielsen SF, Nordestgaard BG, Bojesen SE. 2012. Statin use and reduced cancerrelated mortality. N Engl J Med. 367(19):1792-1802.
74. Novak A, Binnington B, Ngan B, Chadwick K, Fleshner N, Lingwood CA. 2013. Cholesterol masking membrane glycosphingolipid tumor-associated antigens reduces their immunodetection in human cancer biopsies. Glycobiology. 23(11):1230-1239.
75. Nozaki H, Yanagida M, Koide K, Shiotani K, Kinoshita M, Kobayashi Y, Watarai S, Nakamura K, Suzuki A, Ariga T, et al. 2010. Production and characterization of monoclonal antibodies specific to lactotriaosylceramide. Glycobiology. 20(12):1631-1642.
76. Nutikka A, Binnington-Boyd B, Lingwood CA. 2003. Methods for the purification of Shiga toxin 1. In: Philpot D, Ebel F, editors. Methods Mol Med. 73 E. coli Shiga Toxin Methods and Protocols. Totowa, NY, Humana Press. p. 187-195.
77. Orci L, Montesano R, Meda P, Malaisse-Lagae F, Brown D, Perrelet A, Vassalli P. 1981. Heterogeneous distribution of filipin-cholesterol complexes across the cisternae of the Golgi apparatus. Proc Natl Acad Sci USA. 78(1):293-297.
78. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. 2007. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem. 282(37):26832-26844.
79. Page AV, Liles WC. 2013. Enterohemorrhagic Escherichia coli infections and the hemolytic-uremic syndrome. Med Clin N Am. 97(4):681-695, xi.
80. Paliani U, Ricci S. 2012. The role of statins in stroke. Intern Emerg Med. 7(4):305-311.
81. Perez-Sala D, Mollinedo F. 1994. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun. 199(3):1209-1215.
82. Perry RJ, Ridgway ND. 2005. Molecular mechanisms and regulation of ceramide transport. Biochim Biophys Acta. 1734(3):220-234.
83. Pfeffer SR. 2012. Rab GTPase localization and Rab cascades in Golgi transport. Biochem Soc Trans. 40(6):1373-1377.
84. Quinn PJ. 2010. A lipid matrix model of membrane raft structure. Prog Lipid Res. 49(4):390-406.
85. Radin NS. 1994. Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol. 21(2-3):111-127.
86. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. 2012. Effect of statins on venous thromboembolic events: A meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med. 9(9): e1001310.
87. Rendon WO, Martinez-Alonso E, Tomas M, Martinez-Martinez N, Martinez-Menarguez JA. 2013. Golgi fragmentation is Rab and SNARE dependent in cellular models of Parkinson's disease. Histochem Cell Biol. 139(5):671-684.
88. Saito M, MylvaganumM, Tam P, Binnington B, Lingwood C. 2012. Structuredependent pseudo-receptor intracellular traffic of adamantyl globotriaosyl ceramide mimics. J Biol Chem. 287(20):16073-16087.
89. Sandvig K, Spilsberg B, Lauvrak SU, Torgersen ML, Iversen TG, van Deurs B. 2004. Pathways followed by protein toxins into cells. Int J Med Microbiol. 293(7-8):483-490.
90. Sexton RC, Panini SR, Azran F, Rudney H. 1983. Effects of 3 beta-[2-(diethylamino)ethoxy]androst-5-en-17-one on the synthesis of cholesterol and ubiquinone in rat intestinal epithelial cell cultures. Biochemistry. 22(25):5687-5692.
91. SiddiqueMM, Bikman BT,Wang L, Ying L, Reinhardt E, Shui G,WenkMR, Summers SA. 2012. Ablation of dihydroceramide desaturase confers resistance to etoposide-induced apoptosis in vitro. PLoS One. 7(9): e44042.
92. Sillence DJ. 2013. Glucosylceramide modulates endolysosomal pH in Gaucher disease. Mol Genet Metab. 109:194-200.
93. Sillence DJ, Puri V, Marks DL, Butters TD, Dwek RA, Pagano RE, Platt FM. 2002. Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res. 43(11):1837-1845.
94. Solter D, Knowles BB. 1978. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci USA. 75(11): 5565-5569.
95. Son MJ,Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4(5):440-452.
96. Stenmark H, Olkkonen VM. 2001. The Rab GTPase family. Genome Biology. 2(5):Reviews 3007.1-reviews3007.7.
97. Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A, Saito M, Ohtsuka Y, et al. 2002. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem. 277(5):3085-3092.
98. Takahashi M, Kobayashi T. 2009. Cholesterol regulation of rab-mediated sphingolipid endocytosis. Glycoconj J. 26(6):705-710.
99. Tam P, Mahfoud R, Nutikka A, Khine A, Binnington B, Paroutis P, Lingwood C. 2008. Differential intracellular trafficking and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide-containing lipid assemblies. J Cell Physiol. 216:750-763.
100. Tartakoff AM, Vassalli P. 1983. Lectin-binding sites as markers of Golgi subcompartments: Proximal-to-distal maturation of oligosaccharides. J Cell Biol. 97(4):1243-1248.
101. Tepper AD, Diks SH, van Blitterswijk WJ, Borst J. 2000. Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens. J Biol Chem. 275(44): 34810-34817.
102. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al. 1996. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 2(3):483-491.
103. Togayachi A, Akashima T, Ookubo R, Kudo T, Nishihara S, Iwasaki H, Natsume A, Mio H, Inokuchi J, Irimura T, et al. 2001. Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids. J Biol Chem. 276(25):22032-22040.
104. Tuuf J, Mattjus P. 2014. Membranes and mammalian glycolipid transferring proteins. Chem Phys Lipids. 178:27-37.
105. Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, Ichikawa S, Hirabayashi Y, Holleran WM, Okazaki T. 2004. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res. 64(17):6271-6279.
106. Uliana AS, Crespo PM, Martina JA, Daniotti JL, Maccioni HJ. 2006. Modulation of GalT1 and SialT1 sub-Golgi localization by SialT2 expression reveals an organellar level of glycolipid synthesis control. J Biol Chem. 281(43):32852-32860.
107. Vieira KP, de Almeida e Silva Lima Zollner AR, Malaguti C, Vilella CA, de Lima Zollner R. 2008. Ganglioside GM1 effects on the expression of nerve growth factor (NGF), Trk-A receptor, proinflammatory cytokines and on autoimmune diabetes onset in non-obese diabetic (NOD) mice. Cytokine. 42(1):92-104.
108. Wang Z,Wen L,MaX, Chen Z, Yu Y, Zhu J,Wang Y, Liu Z, Liu H,WuD, et al. 2012. High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients. Glycobiology. 22(7):930-938.
109. Warnock D, Lutz M, Blackburn W, Young W, Baenziger J. 1994. Transport of newly synthesized glucosyl ceramide to the plasma membrane by a non-Golgi pathway. Proc Natl Acad Sci USA. 91:2708-2712.
110. White J, Johannes L, Mallard F, Girod A, Grill S, Reinsch S, Kelles P, Echard A, Goud B, Stelzer EHK. 1999. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. J Cell Biol. 147:743-759.
111. Wilson BS, Nuoffer C, Meinkoth JL, McCaffery M, Feramisco JR, Balch WE, Farquhar MG. 1994. A Rab1 mutant affecting guanine nucleotide exchange promotes disassembly of the Golgi apparatus. J Cell Biol. 125(3):557-571.
112. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ. 2001. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 7(7):2067-2075.
113. Xu Y, Martin S, James DE, HongW. 2002. GS15 forms a SNARE complex with syntaxin 5, GS28, and Ykt6 and is implicated in traffic in the early cisternae of the Golgi apparatus. Mol Biol Cell. 13(10):3493-3507.
114. Yahi N, Aulas A, Fantini J. 2010. How cholesterol constrains glycolipid conformation for optimal recognition of Alzheimer's beta amyloid peptide (Abeta1-40). PLoS One. 5(2):e9079.
115. Yegneswaran S, Deguchi H, Griffin JH. 2003. Glucosylceramide, a neutral glycosphingolipid anticoagulant cofactor, enhances the interaction of human-and bovine-activated protein C with negatively charged phospholipid vesicles. J Biol Chem. 278(17):14614-14621.
116. Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, Siegel C, Shayman JA, Arbeeny CM, Kim JK, Jiang C, et al. 2010. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One. 5(6):e11239.
117. Zerial M, McBride H. 2001. Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 2:107-117.